Background: Many studies have demonstrated that the specific method of wound dressing used may affect the healing process. However, the effect of the method of wound dressings on the expression of growth factors is not well documented.
Objective: The aim of this study was to evaluate the effects of different methods of treatment on the healing process and the expression of growth factors (epidermal growth factor, basic fibroblast growth factor, transforming growth factor-beta(2) [TGF-beta(2)], platelet-derived growth factor-A, and platelet-derived growth factor-B) by histologic study, immunohistochemistry, and reverse transcription-polymerase chain reaction.
Methods: In this study, we produced wounds with a CO(2) laser on the backs of rats and used 4 different methods of wound treatment: occlusive dressing material, petrolatum ointment, beta-sitosterol ointment, and exposure to air (untreated) as a control. Five-millimeter biopsy specimens were obtained 1, 3, 5, 7, and 10 days after surgery for histologic evaluation and expression of growth factors from four different dressing sites.
Results: By microscopic examination, there was an acceleration of wound healing in the occlusive dressing wounds, as well as a lesser improvement in healing times with the petrolatum and beta-sitosterol-treated wounds, compared with the air-exposed control subjects. With immunohistochemistry, we observed that the tissue expression of TGF-beta(2) remained at a clearly lower level during the entire duration of wound healing in the occlusive dressing wound compared with the other treatment wounds. With reverse transcriptase-polymerase chain reaction, however, our data did not reveal statistically significant differences among the messenger RNA levels.
Conclusions: Our results suggest that a decrease in the expression level of TGF-beta(2) under occlusive dressings could provide an environment in which the growth of human epidermal keratinocytes and re-epithelialization is promoted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.asj.2006.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of the Top Articles and Authors of the Journal of Orthopaedic Trauma and Bibliometric Comparison of Impact Factors of Orthopaedic Surgery Journals.
J Orthop Trauma
January 2025
Department of Orthopaedic Surgery, Medical City Denton, 3535 S Interstate 35, Denton, TX 76210, United States.
Objectives: To determine the top 100 cited authors and the top 20 articles in the Journal of Orthopaedic Trauma (JOT) and compare its impact factor to orthopaedic and non-orthopaedic surgery literature.
Design: Review.
Methods: The Web of Science database was used to determine the top 100 cited authors and top 20 cited articles that originated in JOT from 1995 to the present.
Nanoparticle encapsulation enables systemic IGF-Trap delivery to inhibit intra-cerebral glioma growth.
Neuro Oncol
January 2025
Department of Medicine, Division of Experimental Medicine, McGill University.
Background: Glioblastoma is an aggressive brain cancer with a 5-year survival rate of 5-10%. Current therapeutic options are limited, due in part to drug exclusion by the blood-brain barrier, restricting access of targeted drugs to the tumor. The receptor for the type 1 insulin-like growth factor (IGF-1R) was identified as a therapeutic target in glioblastoma.
View Article and Find Full Text PDFFirst-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
J Clin Oncol
January 2025
Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of China, Shatin, Hong Kong Special Administrative Region, China.
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.
View Article and Find Full Text PDFSpecific immunohistochemical expression of Mmp-26 in prostatic adenocarcinoma.
An Acad Bras Cienc
January 2025
Universidade Federal de Pernambuco, Departamento de Histologia e Embriologia, Av. Prof. Moraes Rego, 1235, Cidade Universitária, 50760-420 Recife, PE, Brazil.
Matrix metalloproteinases (MMP) have been identified as biomarkers for several diseases, including cancer. The increase in the expression of these enzymes has been related to greater tumor aggressiveness. MMP-26 is expressed constitutively in the endometrium and some cancer cells of epithelial origin.
View Article and Find Full Text PDFThe relationship between insulin resistance and fibroblast growth factor 23 in patients with non-diabetic pre-dialysis chronic kidney disease: a cross-sectional study.
Sao Paulo Med J
January 2025
Associate Professor, Department of Nephrology, Ankara Bilkent City Hospital, Ankara, Turkey.
Background: Insulin resistance often occurs in patients with chronic kidney disease (CKD) owing to mineral and bone metabolism disorders. Fibroblast growth factor (FGF)-23 and soluble klotho (s-KL) play crucial roles in linking CKD with mineral and bone metabolism.
Objective: This study aimed to examine the relationship between insulin resistance and FGF-23 and s-KL in patients with non-diabetic pre-dialysis patients with CKD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!